Literature DB >> 34249434

Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.

Wei Zhang1,2, Donge Tang1, Liewen Lin1, Tingting Fan3, Ligang Xia1, Wanxia Cai1, Weier Dai4, Chang Zou1, Lianghong Yin5, Yong Xu6, Yong Dai1.   

Abstract

Mitochondria play leading roles in initiation and progression of colorectal cancer (CRC). Proteogenomic analyses of mitochondria of CRC tumor cells would likely enhance our understanding of CRC pathogenesis and reveal new independent prognostic factors and treatment targets. However, comprehensive investigations focused on mitochondria of CRC patients are lacking. Here, we investigated global profiles of structural variants, DNA methylation, chromatin accessibility, transcriptome, proteome, and phosphoproteome on human CRC. Proteomic investigations uncovered greatly diminished mitochondrial proteome size in CRC relative to that found in adjacent healthy tissues. Integrated with analysis of RNA-Seq datasets obtained from the public database containing mRNA data of 538 CRC patients, the proteomic analysis indicated that proteins encoded by 45.5% of identified prognostic CRC genes were located within mitochondria, highlighting the association between altered mitochondrial function and CRC. Subsequently, we compared structural variants, DNA methylation, and chromatin accessibility of differentially expressed genes and found that chromatin accessibility was an important factor underlying mitochondrial gene expression. Furthermore, phosphoproteomic profiling demonstrated decreased phosphorylation of most mitochondria-related kinases within CRC versus adjacent healthy tissues, while also highlighting MKK3/p38 as an essential mitochondrial regulatory pathway. Meanwhile, systems-based analyses revealed identities of key kinases, transcriptional factors, and their interconnections. This research uncovered a close relationship between mitochondrial dysfunction and poor CRC prognosis, improve our understanding of molecular mechanism underlying mitochondrial linked to human CRC, and facilitate identifies of clinically relevant CRC prognostic factors and drug targets. AJCR
Copyright © 2021.

Entities:  

Keywords:  Mitochondria; colorectal cancer; drug targets; multi-omics; prognosis

Year:  2021        PMID: 34249434      PMCID: PMC8263689     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  54 in total

Review 1.  The Mitochondrion as an Emerging Therapeutic Target in Cancer.

Authors:  Katherine G Roth; Isa Mambetsariev; Prakash Kulkarni; Ravi Salgia
Journal:  Trends Mol Med       Date:  2019-07-18       Impact factor: 11.951

Review 2.  Immunotherapy in colorectal cancer: rationale, challenges and potential.

Authors:  Karuna Ganesh; Zsofia K Stadler; Andrea Cercek; Robin B Mendelsohn; Jinru Shia; Neil H Segal; Luis A Diaz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06       Impact factor: 46.802

Review 3.  Mitochondria and Cancer.

Authors:  Sejal Vyas; Elma Zaganjor; Marcia C Haigis
Journal:  Cell       Date:  2016-07-28       Impact factor: 41.582

4.  Elucidation of cGMP-dependent induction of mitochondrial biogenesis through PKG and p38 MAPK in the kidney.

Authors:  Pallavi Bhargava; Jaroslav Janda; Rick G Schnellmann
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-16

5.  Phospho-mTOR expression in human glioblastoma microglia-macrophage cells.

Authors:  Lucia Lisi; Gabriella Maria Pia Ciotti; Marta Chiavari; Michela Pizzoferrato; Annunziato Mangiola; Sergey Kalinin; Douglas L Feinstein; Pierluigi Navarra
Journal:  Neurochem Int       Date:  2019-06-10       Impact factor: 3.921

6.  A systematic review of genes affecting mitochondrial processes in cancer.

Authors:  Maricruz Sepulveda-Villegas; Rocio Rojo; Debora Garza-Hernandez; Mauricio de la Rosa-Garza; Victor Treviño
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-05-28       Impact factor: 5.187

Review 7.  mTOR: Role in cancer, metastasis and drug resistance.

Authors:  Avaniyapuram Kannan Murugan
Journal:  Semin Cancer Biol       Date:  2019-08-10       Impact factor: 15.707

Review 8.  Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.

Authors:  Kathryn G Foster; Diane C Fingar
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

9.  Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Thomas A Abrams; Rebecca Miksad; Lawrence S Blaszkowsky; Jeffrey A Meyerhardt; Hui Zheng; Alona Muzikansky; Jeffrey W Clark; Eunice L Kwak; Deborah Schrag; Kathryn R Jors; Charles S Fuchs; A John Iafrate; Darrell R Borger; David P Ryan
Journal:  Cancer       Date:  2011-04-27       Impact factor: 6.860

Review 10.  Energy metabolism in tumor cells.

Authors:  Rafael Moreno-Sánchez; Sara Rodríguez-Enríquez; Alvaro Marín-Hernández; Emma Saavedra
Journal:  FEBS J       Date:  2007-03       Impact factor: 5.542

View more
  3 in total

1.  Multi-Platform-Based Analysis Characterizes Molecular Alterations of the Nucleus in Human Colorectal Cancer.

Authors:  Wei Zhang; Minmin Wu; Xucan Gao; Chiyu Ma; Huixuan Xu; Liewen Lin; Jingquan He; Wanxia Cai; Yafang Zhong; Donge Tang; Min Tang; Yong Dai
Journal:  Front Cell Dev Biol       Date:  2022-02-21

2.  Multi-platform-based characterization of ferroptosis in human colorectal cancer.

Authors:  Yafang Zhong; Wei Zhang; Haiyan Yu; Liewen Lin; Xucan Gao; Jingquan He; Dandan Li; Yumei Chen; Zhipeng Zeng; Yong Xu; Donge Tang; Yong Dai
Journal:  iScience       Date:  2022-07-15

3.  Integrated computer analysis and a self-built Chinese cohort study identified GSTM2 as one survival-relevant gene in human colon cancer potentially regulating immune microenvironment.

Authors:  Wei Zhang; Yutong Shi; Shumeng Niu; Lintai Li; Liewen Lin; Xucan Gao; Wanxia Cai; Yumei Chen; Yafang Zhong; Donge Tang; Min Tang; Yong Dai
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.